Mankind Pharma Reports 11.5% YoY Revenue Growth in Q3FY26, Adj. EBITDA Margin at 25.9%
Mankind Pharma, one of India's largest pharmaceutical companies, has announced its financial results for Q3FY26. The company reported a revenue increase of 11.5% YoY, with adjusted EBITDA margins of 25.9%. The growth was primarily due to improvement in domestic pharma and BSV consolidation. The chronic share increased by 200bps YoY to 39.3%, driven by strong growth of 16.7% in cardiac and 14.4% in anti-diabetes. The revenue from OTC grew by 5.2% in Q3FY26 vs -2.6% in Q2FY26. The BSV growth initiatives are progressing well, with a strong double-digit growth in Q3. The company remains confident of delivering long term sustainable growth anchored by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and super specialty BSV portfolio.
Key Highlights
- Revenue from Operations at INR 3,567 Cr, up by 11.5% YoY
- Adjusted EBITDA margin of 25.9% and PAT margin of 11.6%
- Domestic revenue at INR 3,046 Cr, up 11.1%, Exports at INR 521 Cr, up 14.1% YoY
- Strong growth in chronic therapies: 16.7% in Cardiac and 14.4% in Anti-Diabetes
- BSV growth initiatives progressing well with strong double-digit growth in Q3